Mydriasis

The FDA accepted a new drug application for Nyxol for the reversal of pharmacologically induced mydriasis, according to a press release from Ocuphire Pharma.

Ocuphire Pharma and FamyGen Life Sciences have entered into a global licensing agreement that will allow Famy to fund and commercialize the development of Nyxol eye drops in the U.S. as well as globally, according to a press release.

I would like to congratulate Mitch Jackson on his 100th Premium Channel column in OSN. Mitch’s entertaining approach to presenting cutting-edge techniques and technology in premium refractive surgery has always matched his ebullient personality.

NEW YORK — In this Healio Video Perspective from the ASRS meeting, David S. Boyer, MD, discusses the results of the MIRA-2 and MIRA-3 studies investigating phentolamine as a treatment for reversing pharmacologically induced mydriasis.

Three years ago, tragedy struck my family with the loss of my brother due to metastatic lung cancer.

Nyxol demonstrated positive results in a pediatric safety trial to reverse pharmacologically induced mydriasis, according to a press release from Ocuphire Pharma.

NEW YORK – A phase 3 FDA registration trial for Ocuphire Pharma’s Nyxol yielded positive topline results for the reversal of mydriasis, according to a company executive.

In a second phase 3 registration trial, Nyxol helped reverse pharmacologically induced mydriasis at 90 minutes, according to a press release from Ocuphire Pharma.

Nyxol, an alpha 1/2 antagonist eye drop, helped reverse the effects of pharmacologically induced mydriasis in healthy subjects, according to a phase 3 study.

In this video, Jay S. Pepose, MD, PhD, discusses research on new indications for the use of phentolamine for the rapid reversal of mydriasis after ocular examination and for the reduction of nocturnal visual disturbances.